Yi, Tae WonTae WonYiSmyth, BrendanBrendanSmythDi Tanna, Gian LucaGian LucaDi TannaArnott, ClareClareArnottCardoza, KathrynKathrynCardozaKang, AmyAmyKangPollock, CarolCarolPollockAgarwal, RajivRajivAgarwalBakris, GeorgeGeorgeBakrisCharytan, David MDavid MCharytande Zeeuw, DickDickde ZeeuwHeerspink, Hiddo J LHiddo J LHeerspinkNeal, BruceBruceNealWheeler, David CDavid CWheelerCannon, Christopher PChristopher PCannonZhang, HongHongZhangZinman, BernardBernardZinmanPerkovic, VladoVladoPerkovicLevin, AdeeraAdeeraLevinMahaffey, Kenneth WKenneth WMahaffeyJardine, MegMegJardineLEE-MING CHUANG et al.2023-07-172023-07-172023-0702726386https://scholars.lib.ntu.edu.tw/handle/123456789/633798It is unclear whether the effect of canagliflozin on adverse kidney and cardiovascular events in those with diabetic kidney disease varies by age and sex. We assessed the effects of canagliflozin among age group categories and between sexes in the Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study.enDiabetic kidney disease; age; canagliflozin; cardiovascular outcomes; chronic kidney disease; diabetes; kidney outcomes; sex; sodium/glucose cotransporter 2 inhibitorsjournal article10.1053/j.ajkd.2022.12.015368894252-s2.0-85153964624https://api.elsevier.com/content/abstract/scopus_id/85153964624